Cb-839 In Combination With Cabozantinib In Patients With Clear Cell And Papillary Metastatic Ren...

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic ren...

Dr. Meric-Bernstam on CB-839 Plus Cabozantinib in RCC

Promising results of cabozantinib plus nivolumab in non-clear cell RCC

Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCC

Dr. Meric-Bernstam on the Activity of Telaglenastat and Cabozantinib in mRCC

CARINA: cabozantinib post first-line immune-oncology CPI-containing combination in aRCC

Cabozantinib in mRCC

Targeted Oncology

Clinical Decisions in Patients With RCC Bone Metastases

Targeted Oncology

Anti-Tumor Activity of Small Molecule Glutaminase Inhibitors: Role of Telaglenastat (CB-839) in RCC

Kidney Cancer Association

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma

Telaglenastat Plus Cabozantinib for Advanced Renal Cell Carcinoma

How Cabozantinib is Being Used in Practice for Patients With RCC

Targeted Oncology

Cabozantinib in mRCC

Kidney Cancer Drug Shows Early Promise

HealthFeed Network

The Rationale for Using Cabozantinib

Targeted Oncology

Other Clinical Trials in Renal Cell Carcinoma

Nivolumab Plus Cabozantinib for Patients With Non-Clear Cell Renal Cell Carcinoma

Dr. McGregor on the Future of Cabozantinib in RCC

CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC

Managing side effects of cabozantinib treatment for metastatic renal cell carcinoma